Equities

Incannex Healthcare Inc

IXHL:NMQ

Incannex Healthcare Inc

Actions
  • Price (USD)1.95
  • Today's Change0.05 / 2.63%
  • Shares traded10.96k
  • 1 Year change-59.38%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2023
  • Employees--
  • Location
    Incannex Healthcare Inc18 East 50th Street, 5th FloorNEW YORK 10022United StatesUSA
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TherapeuticsMD Inc996.00k-4.83m19.72m1.00--0.7127--19.80-0.4348-0.55380.08892.400.0212--0.5048996,000.00-10.31-53.35-13.13-111.6145.0886.67-485.34-236.57----0.00---98.14-39.53-816.85------
Cyclo Therapeutics Inc1.13m-20.74m20.37m8.00------17.99-0.9104-0.91040.0474-0.17850.2420.400213.16141,553.80-443.08-132.22---215.1791.5690.37-1,831.29-1,114.040.4283-------21.761.25-29.81---3.95--
China Health Industries Holdings, Inc.95.95k-1.36m21.30m32.00------221.99-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
BioXcel Therapeutics Inc2.40m-107.83m23.49m74.00------9.78-3.56-3.560.074-1.840.02340.59413.8732,472.97-104.93-74.57-150.29-84.0643.07---4,487.39-32,300.742.25-10.103.59--268.00---8.02---43.26--
Polypid Ltd0.00-24.70m24.33m59.00--10.37-----9.65-9.650.000.33370.00----0.00-107.89-76.92-164.39-89.61-----------24.210.8425------39.67---42.34--
Bio Essence Corp593.21k-1.02m25.09m12.00------42.29-0.0278-0.01560.0158-0.04580.3305--21.20---57.09-46.10----25.0533.89-172.74-111.21---59.997.03---11.27-10.94-52.03---48.19--
KALA BIO Inc0.00-38.72m26.68m43.00--1.94-----13.95-13.950.002.980.00----0.00-60.45-57.83-78.16-69.32--57.06---1,553.61---11.360.7174---100.00--5.85---17.31--
Acasti Pharma Inc0.00-11.45m27.17m32.00--0.4578-----1.22-1.220.005.850.00-------16.04-31.68-16.57-33.95-------56,271.43---37.800.00------69.71---47.16--
Dare Bioscience Inc2.84m-7.20m27.86m23.00--10.43--9.81-1.07-1.070.35790.31260.1213--3.85123,462.20-30.76-109.51-191.39-246.260.8477---253.60-1,104.55----0.00---71.92--2.54--121.37--
Equillium Inc42.62m-8.32m30.11m45.00--1.34--0.7064-0.2377-0.23771.200.63330.8388--8.85968,704.60-16.37-46.81-29.58-57.36-----19.52-328.35----0.00--128.97--78.64--7.48--
Incannex Healthcare Inc-100.00bn-100.00bn30.95m----2.19----------0.8907-----------54.94---59.47-------1,033.07----0.00--61.923.38-24.35--54.12--
Fortress Biotech Inc82.62m-49.54m34.11m186.00--1.89--0.4128-3.71-3.716.050.79150.50632.366.07444,215.10-65.90-52.50-113.69-99.4668.7763.17-130.17-236.941.24-13.401.26--11.5825.7527.42---9.37--
Ocuphire Pharma Inc16.45m-14.11m36.42m14.00--0.8886--2.21-0.5507-0.55070.68711.560.3726--6.531,174,929.00-31.95-58.31-36.01-65.94-----85.75-137.92---10.800.00---52.20---155.83------
Eyenovia Inc31.41k-37.28m38.53m57.00------1,226.56-0.7897-0.78970.0007-0.04250.0013--0.0418551.05-154.24-80.31-262.28-117.70-1,489.11---118,693.60-680.950.267-40.921.20------2.68--152.20--
Natural Alternatives International, Inc.120.20m-3.31m41.86m317.00--0.497731.190.3482-0.5646-0.564620.5313.560.80913.6312.77379,183.00-2.234.90-2.565.938.8515.98-2.753.802.44-2.710.09960.00-9.913.06-76.46-20.7427.08--
Data as of Sep 20 2024. Currency figures normalised to Incannex Healthcare Inc's reporting currency: US Dollar USD

Institutional shareholders

3.03%Per cent of shares held by top holders
HolderShares% Held
Tidal Investments LLCas of 30 Jun 2024280.62k1.59%
AdvisorShares Investments LLCas of 30 Jun 202480.00k0.45%
Old Mission Capital LLCas of 30 Jun 202468.68k0.39%
HRT Financial LLCas of 30 Jun 202443.93k0.25%
Morgan Stanley & Co. LLCas of 30 Jun 202429.85k0.17%
Barclays Capital Securities Ltd.as of 30 Jun 202422.50k0.13%
UBS Securities LLCas of 30 Jun 20246.00k0.03%
1st Capital Management Group GmbHas of 31 Jul 2024800.000.01%
Qube Research & Technologies Ltd.as of 30 Jun 2024717.000.00%
Macquarie Investment Management Business Trustas of 30 Jun 2024598.000.00%
More ▼
Data from 30 Jun 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.